Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 11/20 | 0.42 |
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | DRD3 | P35462 | 5/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10830907 | 0.83 | HTR3A (0.47) | HTR3AADRB2HTR1ADRD2DRD3 | |
| SCHEMBL4850347 | 0.80 | HTR1A (0.55) | HTR1ADRD2DRD3 | |
| SCHEMBL7160420 | 0.76 | PARP1 (0.52) | HTR3A | |
| SCHEMBL2085575 | 0.76 | HTR3A (0.47) | HTR3AADRB2HTR1ADRD2DRD3 | |
| SCHEMBL4573122 | 0.75 | HTR1A (0.54) | HTR1ADRD2DRD3 | |
| SCHEMBL12628017 | 0.75 | MAPT (0.42) | HTR3AADRB2HTR1ADRD2DRD3 | |
| SCHEMBL12628018 | 0.74 | ADRB2 (0.43) | HTR3AADRB2HTR1ADRD2DRD3 | |
| SCHEMBL15840472 | 0.74 | HTR3A (0.51) | HTR3AADRB2HTR1ADRD2DRD3 | |
| SCHEMBL134748 | 0.74 | HTR3A (0.43) | HTR3AADRB2HTR1ADRD2DRD3 | |
| SCHEMBL97548 | 0.74 | HTR3A (0.43) | HTR3AADRB2HTR1ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2535340-B1 | Process for making zilpaterol and salts thereof | INTERVET INT BV (NL) | 2016-04-27 | — | — | EP | claimed |
| EP-2142553-B1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | INTERVET INT BV (NL) | 2015-08-19 | — | — | EP | claimed |
| US-8362006-B2 | Processes for making zilpaterol and salts thereof | INTERVET INTERNATIONAL B.V. (NL) | 2013-01-29 | — | — | US | claimed |
| EP-2535340-A2 | Process for making zilpaterol and salts thereof | Intervet International B.V. (NL) | 2012-12-19 | — | — | EP | claimed |
| US-20100121050-A1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | INTERVET INTERNATIONAL B.V. (NL) | 2010-05-13 | — | — | US | claimed |
| EP-2142553-A1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | Intervet International B.V. (NL) | 2010-01-13 | — | — | EP | claimed |
| WO-2008119754-A1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | INTERVET INTERNATIONAL B.V. (NL) | 2008-10-09 | — | — | WO | claimed |
| EP-3190114-B1 | PROCESS FOR MAKING A CRYSTALLINE ZILPATEROL SALT | INTERVET INT BV (NL) | 2019-11-06 | — | — | EP | disclosed |
| EP-3190114-B1 | PROCESS FOR MAKING A CRYSTALLINE ZILPATEROL SALT | INTERVET INT BV (NL) | 2019-11-06 | — | — | EP | disclosed |
| EP-2935275-B9 | AN IMPROVED PROCESS FOR MAKING ZILPATEROL | INTERVET INT BV (NL) | 2017-10-11 | — | — | EP | disclosed |
| EP-2935275-B9 | AN IMPROVED PROCESS FOR MAKING ZILPATEROL | INTERVET INT BV (NL) | 2017-10-11 | — | — | EP | disclosed |
| EP-3190114-A1 | PROCESS FOR MAKING A CRYSTALLINE ZILPATEROL SALT | Intervet International B.V. (NL) | 2017-07-12 | — | — | EP | disclosed |
| EP-3190114-A1 | PROCESS FOR MAKING A CRYSTALLINE ZILPATEROL SALT | Intervet International B.V. (NL) | 2017-07-12 | — | — | EP | disclosed |
| US-20080161288-A1 | COMPOUNDS | PFIZER INC. | 2008-07-03 | — | — | US | disclosed |
| WO-2008050207-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANABOLIC AGENTS FOR LIVESTOCK ANIMALS | PFIZER LIMITED (GB) | 2008-05-02 | — | — | WO | disclosed |
| US-20080103130-A1 | 7-hydroxy-6-{[1-methyl-3-(1,3-thiazol-5-yl)propyl]amino}-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1]benzazepin-2(1H)-one; agonists at the beta-2 adrenoceptor; feed additives for livestock animals; improving meat yield or meat quality | PFIZER LIMITED (GB) | 2008-05-01 | — | — | US | disclosed |
| US-20080103130-A1 | 7-hydroxy-6-{[1-methyl-3-(1,3-thiazol-5-yl)propyl]amino}-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1]benzazepin-2(1H)-one; agonists at the beta-2 adrenoceptor; feed additives for livestock animals; improving meat yield or meat quality | PFIZER LIMITED (GB) | 2008-05-01 | — | — | US | disclosed |
| US-20080103130-A1 | 7-hydroxy-6-{[1-methyl-3-(1,3-thiazol-5-yl)propyl]amino}-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1]benzazepin-2(1H)-one; agonists at the beta-2 adrenoceptor; feed additives for livestock animals; improving meat yield or meat quality | PFIZER LIMITED (GB) | 2008-05-01 | — | — | US | disclosed |
| WO-2008044127-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANABOLIC AGENTS FOR LIVESTOCK ANIMALS | PFIZER LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| US-4585770-A | HYPOTENSIVES, VASODILATORS | ROUSSEL UCLAF (FR) | 1986-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103130-A1 | 7-hydroxy-6-{[1-methyl-3-(1,3-thiazol-5-yl)propyl]amino}-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1]benzazepin-2(1H)-one; agonists at the beta-2 adrenoceptor; feed additives for livestock animals; improving meat yield or meat quality | ADRB2, ADRB1, ADRA2C | HTR3A 339/4885ADRB2 1/4885HTR1A 128/4885 |
| US-20100121050-A1 | PROCESSES FOR MAKING ZILPATEROL AND SALTS THEREOF | SLC39A11, SLC39A3, ZFR | HTR3A 4366/4885ADRB2 1749/4885HTR1A 4109/4885 |
| US-20080161288-A1 | COMPOUNDS | ADRB2, ADRB1, ADRA2C | HTR3A 469/4885ADRB2 1/4885HTR1A 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.